本文へ移動
cccskills
無料GitHub で公開

pediatric-obesity-intervention-selector

Select the right treatment tier for a child with obesity — behavioural, pharmacologic, or surgical — using the CMAJ 2025 pediatric obesity guideline. Trigger when a clinician asks what to do for a child with obesity, which intervention to start, whether to escalate treatment, or when to consider medication or surgery for pediatric obesity.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md5.0 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Pediatric Obesity: Intervention Selector

Step-by-step guide to selecting the appropriate intervention tier for a child (0–18 years) with obesity. Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456).

Step 1 — Gather Key Information

Before recommending anything, confirm:

  • Age (years)
  • BMI z-score (BMIz) using WHO growth charts for Canada
  • What has already been tried (duration, adherence, response)
  • Comorbidities (metabolic, mechanical, mental health — see 4Ms below)
  • Family preferences and values — what outcomes matter most to them?
  • Social determinants (food security, neighbourhood, family dynamics)

⚠️ Use person-first, neutral language throughout. Say "child with obesity" not "obese child." Refer to BMI, weight, or growth — not "fat" or "overweight."

Step 2 — First-Line: Behavioural & Psychological Interventions

All children with obesity, regardless of age. Strong recommendation, very low to moderate certainty.

Recommend a multicomponent intervention — must include at least 2 of:

  • Physical activity
  • Nutrition counselling
  • Psychological support (e.g., CBT, motivational interviewing)
  • Technology-assisted components (optional; weak evidence)

Individual components alone (nutrition-only, exercise-only) are conditional recommendations with weaker evidence — prefer multicomponent.

Practical targets:

  • Higher-intensity sessions (aerobic + resistance training) superior to low-intensity
  • Goal-setting, self-monitoring, problem-solving, and relapse prevention are effective behaviour change tools
  • At least 26 hours of contact time improves outcomes
  • Long-term support is essential — obesity is chronic and relapsing

Technology interventions alone: Neither for nor against (insufficient evidence).

Step 3 — Escalate to Pharmacotherapy?

Consider if: inadequate response to behavioural/psychological interventions AND age ≥ 12 years.

⚠️ No stepwise requirement — pharmacotherapy can be offered alongside, not only after, behavioural therapy. It must always be combined with behavioural/psychological interventions.

→ Go to the Pharmacotherapy Selector skill for agent selection.

If age < 12: insufficient evidence for any pharmacotherapy — do not prescribe.

Step 4 — Escalate to Surgery?

Consider if: age ≥ 13 years AND deemed eligible after comprehensive multidisciplinary assessment.

⚠️ Surgery does not require prior failure of pharmacotherapy. Consider based on severity, comorbidities, family preference, and centre availability.

Surgical options: Laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB). Both: conditional recommendation, low to moderate certainty.

Requirements before referral:

  • Specialized, multidisciplinary team assessment
  • Psychological/psychiatric clearance
  • Nutritional assessment
  • Family/caregiver involvement and support
  • Shared decision-making about serious AE risk

→ Go to the Surgical Eligibility Screener skill for full checklist.

Step 5 — Shared Decision-Making at Every Tier

At every tier, the conversation matters as much as the prescription:

  • Present all options (behavioural, pharmacologic, surgical) — no option should be withheld from discussion
  • Acknowledge the balance of benefits and harms for each option
  • Align on what success looks like — HRQoL, mood, mobility, not just BMI
  • Involve both child and caregiver in the decision (separately if helpful)
  • Address social determinants that may affect access or adherence
  • Refer to multidisciplinary team where available

Clinical Guardrails

  • Eating disorder vigilance: Ask about binge eating, body image concerns, atypical anorexia — especially before pharmacotherapy or surgery. Refer to specialist if suspected.
  • Don't focus solely on weight. Improved HRQoL, depression, anxiety, and cardiometabolic markers are equally valid outcomes.
  • Obesity is not a personal failing. Genetics, physiology, and environment drive it. Frame this clearly for families.
  • Lipase inhibitors (orlistat): Suggested but not preferred — higher GI side effects and serious AE risk. Use only if GLP-1RA and metformin unavailable.
  • Technology-only interventions: Insufficient evidence — do not use as a standalone strategy.

Source

CMAJ 2025 Clinical Practice Guideline: Managing obesity in children. Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: 10.1503/cmaj.241456 Updated version: June 3, 2025.

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する